Sign in
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Updates from the Field
2020
Retinal Detachment Rates after Intravitreal Anti-VEGF Injections- Dr. Omesh Gupta
Keyvan Koushan, MD, FRCSC
Member Podcasts
TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Category: AMD-Neovascular